How to Get Low-Dose Naltrexone in Michigan

What low-dose naltrexone is, and what it is not

Naltrexone hydrochloride is an opioid receptor antagonist. At 50 mg, it is FDA-approved for maintenance treatment of opioid dependence and for alcohol use disorder, and it carries a boxed warning about hepatotoxicity at that dose [1]. "Low-dose naltrexone" refers to the same molecule prescribed at 1.5 mg to 4.5 mg, a fraction of the approved dose. There is no FDA-approved low-dose naltrexone product. Every LDN prescription is off-label, and because commercial manufacturers do not sell tablets in these strengths, it must be compounded individually by a pharmacy.

Off-label prescribing is legal and common; a widely cited 2006 analysis estimated that roughly one in five outpatient prescriptions in the United States is written off-label [2]. That context matters for LDN specifically because "off-label" here does not mean unstudied. It means the FDA has not evaluated this dose and formulation for these indications, so the evidence supporting it comes from smaller trials and observational studies rather than a drug label.

At sub-therapeutic doses, naltrexone is thought to transiently block opioid receptors, which may trigger a rebound increase in endogenous endorphins and enkephalins and have downstream immune-modulating effects [3]. This mechanism is biologically plausible and supported by small trials, but it is not established at the level of a large confirmatory trial or a professional society treatment guideline for any single condition.

Who can prescribe LDN in Michigan

Any Michigan-licensed prescriber with an active DEA registration can write an LDN prescription: MDs, DOs, nurse practitioners, and physician assistants. Naltrexone is not a scheduled controlled substance, which removes one common barrier to telehealth prescribing.

Michigan expanded nurse practitioner prescriptive authority through state legislation in the mid-2010s [4]. Physician assistants in Michigan prescribe under a collaborative practice agreement with a supervising physician, and that agreement can include authority to prescribe off-label medications such as LDN. Because scope-of-practice rules can be amended, confirm current NP and PA prescribing authority against the Michigan Legislature's published statutes [4] or LARA's licensing guidance [5] rather than relying on a fixed year.

In practice, the harder step for many patients is not licensure but familiarity: many primary care clinicians have limited experience with LDN dosing and titration. Asking a current prescriber is a reasonable first step; if they decline, a telehealth platform focused on LDN, or a compounding pharmacy's referral list, is often a faster path to a prescriber who titrates it routinely.

Does Michigan allow telehealth prescribing for LDN?

Yes, with conditions. Michigan permits telehealth prescribing of medications, including non-controlled substances like naltrexone, through an audio-video visit with a Michigan-licensed provider who conducts an adequate clinical evaluation [5]. Michigan's telehealth parity law also extends to audio-only visits under some circumstances, though most LDN-focused telehealth platforms default to video visits.

The provider must hold an active Michigan license or practice through a recognized interstate licensure compact. After the visit, the prescription is typically sent electronically to a 503A compounding pharmacy the patient chooses or one the platform partners with. Telehealth consultation fees and follow-up cadence vary by platform; treat any specific dollar figure as something to confirm at the time of booking rather than a fixed price.

How Michigan's compounding pharmacies fit in

LDN cannot be filled at a standard retail pharmacy counter because no commercial manufacturer sells naltrexone at 1.5 to 4.5 mg strengths. The prescription must go to a pharmacy compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows pharmacies to prepare patient-specific formulations from a valid prescription [6].

Michigan has licensed 503A compounding pharmacies, and out-of-state 503A pharmacies can also ship into Michigan if they hold the required Michigan Board of Pharmacy registration for out-of-state compounders. The standard formulation is an immediate-release oral capsule; the clinical trial evidence discussed below almost entirely used this form, not sublingual drops, sustained-release capsules, or topical creams, so those alternative formulations carry even less direct evidence behind them.

Compounded medications are not held to the same batch-testing requirements as FDA-approved manufactured drugs. Pharmacies accredited by the Pharmacy Compounding Accreditation Board, or that voluntarily follow USP 795/797 standards, provide some added assurance of potency and sterility, and it is reasonable to ask a pharmacy directly whether it performs third-party potency testing on its naltrexone capsules.

What labs are typically ordered before starting

Most prescribers order baseline labs before starting LDN, commonly a complete blood count, a comprehensive metabolic panel, and liver function tests (AST and ALT). This is a reasonable precaution given naltrexone's boxed warning for hepatotoxicity at the 50 mg dose [1]. LDN doses represent a small fraction of that dose, but baseline liver function still helps a prescriber decide whether LDN is appropriate and gives a reference point for monitoring. Patients with substantially elevated liver enzymes are generally not good candidates until that is addressed.

Depending on the suspected underlying condition, a prescriber may also order thyroid studies or inflammatory markers such as CRP and ESR to establish a baseline that can help gauge response later. None of this is a substitute for individualized clinical judgment by the prescribing clinician, and a reader should not use lab reference ranges from this article to interpret their own results.

Does Michigan Medicaid cover compounded LDN?

Coverage of compounded, off-label medications through Medicaid managed care is a policy detail that changes and is set at the state Medicaid agency level, not something a general article can state with certainty at a point in time. What can be said generally: Medicaid programs typically require prior authorization for compounded and off-label drugs, and a PA request commonly needs a diagnosis code, a medical necessity statement, and documentation that standard therapies were tried first. Specific Michigan Medicaid PA criteria, processing timelines, and appeal windows for LDN should be verified directly with the Michigan Department of Health and Human Services or through LARA's published guidance [5] before a patient or clinic relies on any particular number.

Private commercial insurance coverage of compounded LDN is inconsistent, and many commercial plans exclude compounded medications from coverage regardless of prior authorization. Some patients instead ask about splitting or dissolving a manufactured 50 mg tablet to approximate a lower dose; this is not the studied formulation, produces imprecise dosing, and is not the approach most LDN-experienced prescribers recommend.

How LDN is typically dosed

Most protocols start at 1.5 mg taken once nightly and increase by 1.5 mg every one to two weeks toward a target of 4.5 mg [3]. Nighttime dosing is intentional: the theory is that transient nocturnal opioid receptor blockade triggers a compensatory rise in endogenous opioid signaling overnight, though this mechanism has not been confirmed at the level of a large mechanistic trial in humans.

In the Younger 2013 fibromyalgia trial, side effects during titration were generally mild, with vivid dreams reported by a substantial minority of participants; sleep disturbance, headache, and transient nausea also occurred and typically resolved within one to two weeks [7]. Starting low and titrating slowly is the standard way prescribers reduce the frequency of these effects.

One firm contraindication: patients currently taking opioid medications should not start LDN, because naltrexone will precipitate acute withdrawal even at low doses. A washout period is required before starting, and the necessary length depends on which opioid was used and for how long; this is an individualized decision that requires direct clinical guidance, not a fixed number a patient should apply to themselves [1].

What the trial evidence actually shows, by condition

The core, quotable finding of this page: low-dose naltrexone is FDA-approved only at 50 mg for opioid and alcohol dependence, and its use at 1.5 to 4.5 mg for conditions like fibromyalgia, Crohn's disease, or chronic pain is off-label and supported mainly by small trials and observational reports rather than large confirmatory studies or an FDA indication [1][3][7]. Readers should treat every efficacy figure below as evidence from small studies, not as an established, guideline-endorsed effect size.

Fibromyalgia. Younger and Mackey's 2009 pilot crossover trial (N=10) and a 2013 follow-up crossover trial (N=31) both reported meaningful pain reduction with LDN compared with placebo, with the larger trial reporting a mean pain reduction around 29% versus about 18% for placebo (P = 0.016) [7][8]. Both trials were small, single-site, and used a crossover design, which limits how far the effect size generalizes.

Crohn's disease. An open-label pilot study (N=17) reported high rates of clinical response and remission on 4.5 mg nightly LDN over 12 weeks [9]. A subsequent randomized, placebo-controlled trial (N=40) found a remission rate around 28% with LDN versus 0% with placebo (P < 0.05) [10]. These are still small trials by gastroenterology standards, and larger confirmatory studies have not been widely reported.

Multiple sclerosis. A 2010 pilot study (N=80) found LDN was well tolerated but did not show a statistically significant improvement in quality of life over eight weeks [11]. This is one of the more cautionary data points for LDN: tolerability was fine, but the primary benefit sometimes claimed for MS was not demonstrated in this trial.

Complex regional pain syndrome (CRPS). A 2016 report described low-dose naltrexone as a potential therapy option for CRPS Type I patients [12]. This is preliminary, observational-level evidence; it does not establish efficacy at the level of a randomized trial, and it should be described to patients as an emerging option under investigation rather than a proven treatment.

Chronic pain more broadly. A 2018 narrative review in Medical Science summarized dozens of published reports on LDN across neuropathic pain, CRPS, and autoimmune-related pain and described the overall pattern as suggestive of analgesic and anti-inflammatory activity [13]. A narrative review of this kind is useful for identifying where more rigorous trials are needed; it is not itself trial-level evidence and should not be read as a pooled effect estimate. A separate pharmacotherapy review reached similarly cautious conclusions about safety and the need for larger trials across fibromyalgia, MS, Crohn's disease, and other chronic pain conditions [14].

What is established, what is plausible, and what is not established

Established: Naltrexone at 50 mg is FDA-approved for opioid and alcohol dependence, and it carries a hepatotoxicity warning at that dose [1]. LDN doses are far below that threshold, but there is no FDA-approved low-dose product, and every LDN prescription is off-label. LDN must be compounded by a 503A pharmacy because no commercial low-dose product exists [6]. Naltrexone will precipitate withdrawal in patients currently using opioids [1].

Plausible but unproven at scale: A modest analgesic and anti-inflammatory effect in fibromyalgia and possibly Crohn's disease, based on small randomized trials [7][8][9][10]. A mechanism involving transient opioid receptor blockade and rebound endogenous opioid signaling [3].

Not established: A benefit in multiple sclerosis quality of life in the one available pilot trial [11]. A confirmed benefit in CRPS beyond a single preliminary report [12]. Any specific Michigan Medicaid prior-authorization criterion, approval timeline, or cash price, none of which this article can state with confidence without a direct, dated check against the payer or pharmacy.

Transferring an existing LDN prescription to Michigan

Michigan permits prescription transfers between licensed pharmacies, including compounding pharmacies, provided refills remain on the prescription. If no refills remain, the prescribing clinician needs to issue a new prescription. Confirm the exact administrative rule and any transfer restrictions directly with the Michigan Board of Pharmacy or LARA [5], since regulatory citations and requirements can be updated.

If the existing out-of-state pharmacy is a 503A compounder already registered to ship into Michigan, a formal transfer may not be necessary at all; the same pharmacy may simply be able to ship to a Michigan address once the registration is confirmed.

A realistic timeline, not a guarantee

For a patient starting through telehealth with no existing labs: scheduling a visit (often within a few days), completing labs (typically a day or two for results), the provider visit and e-prescription, and pharmacy compounding and shipping (commonly several business days) add up to roughly one to two weeks from first contact to first dose for many patients. Patients with recent labs on file can often compress this. Treat this as a general planning estimate, not a guarantee tied to any specific platform or pharmacy.

Verification checklist: stable facts vs. facts that change

Some facts about LDN in Michigan come from federal regulation or published clinical trials and are unlikely to change quickly. Others depend on a specific insurer, pharmacy, or platform's current policy and can change without notice. Before acting on anything in this article, or in a conversation with a prescriber, separate the two.

Stable, federally or clinically anchored facts (verify once, unlikely to shift often):

• Naltrexone 50 mg is FDA-approved for opioid and alcohol dependence; LDN is not FDA-approved at any dose [1].
• LDN must be compounded under 503A because no manufacturer sells 1.5 to 4.5 mg tablets [6].
• Naltrexone will precipitate withdrawal in patients currently on opioids [1].
• The core fibromyalgia and Crohn's disease trials cited here are small (N=10 to N=40) and use crossover or single-site designs [7][8][9][10].
• Naltrexone is not a federally scheduled controlled substance.

Date-sensitive facts (reconfirm at the time of the patient's appointment or claim):

• Whether a specific Michigan Medicaid managed care plan covers compounded LDN, and what prior-authorization documentation it currently requires. Confirm with MDHHS or the plan directly.
• Current PA processing time and appeal window for a denial. Confirm with the specific plan.
• Whether a specific compounding pharmacy holds an active Michigan out-of-state registration. Confirm with the pharmacy or the Michigan Board of Pharmacy.
• Current cash price for a month's supply of LDN capsules at a specific pharmacy. Prices vary by pharmacy, dose, and formulation.
• Current telehealth platform consultation and follow-up fees.
• Current scope-of-practice rules for NPs and PAs prescribing off-label medications in Michigan, since these are set by statute and can be amended [4][5].

When this low-dose naltrexone article lacks specific numbers for claims in the second category, this reflects a deliberate choice to avoid stating payer policies or pricing as definitive on a general educational resource.